Navigation Links
Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
Date:6/26/2012

SILVER SPRING, Md., June 26, 2012 /PRNewswire-USNewswire/ -- A new study on the effects of lorcaserin, a drug recently recommended for approval by an FDA advisory panel for the treatment of obesity, was just published in the scientific journal Obesity.  The journal is published by The Obesity Society (TOS), the leading scientific organization in North America dedicated to the study of obesity.  Authors include several TOS members including Patrick O'Neil, PhD, President, and Steven Smith, MD, Vice-President of TOS.

(Logo: http://photos.prnewswire.com/prnh/20120531/DC16753LOGO )

The study, titled BLOOM-DM (Behavioral Modification and Lorcaserin for Obesity and Overweight Management in Diabetes Mellitus) evaluated 604 obese and overweight participants with type 2 diabetes in a double-blind placebo-controlled randomized trial over a one-year treatment period. Although all participants received systematic lifestyle change counseling, those on the medication lost 4.5 – 5.0% of their initial bodyweight compared to a loss of 1.5% by patients on the inactive placebo. According to lead author O'Neil, "That's a very meaningful difference in weight loss for this population. Importantly, the patients on active medication also showed much greater improvement on a key measure of blood glucose control."

Lorcaserin is a selective serotonin receptor agonist that works specifically on appetite signals in the brain. It has been developed by Arena Pharmaceuticals, which sponsored the trial. In previous clinical trials, lorcaserin decreased body weight in non-diabetic overweight and obese individuals. Although current American Diabetes Association treatment guidelines recommend that individuals with type 2 diabetes achieve modest weight loss (5–7%) to improve glycemic control, weight loss has historically been more difficult to achieve among patients with type 2 diabetes than among those without diabetes.

Over 85% of people with type 2 diabetes are overweight and obese people, and they often find weight loss more difficult than do non-diabetics. Weight losses of 5-10% can significantly improve glycemic control as well as other weight-related comorbid conditions. However, diet and exercise alone are often insufficient to achieve such weight losses in this population.  There are a variety of medications approved to treat health risks such as hypertension and hyperlipidemia, yet few have been approved to treat obesity, the greatest health threat of this century.

The Obesity Society is committed to encouraging research on the causes and treatment of obesity.  This new study on lorcaserin is one more example of the important research being conducted by TOS members to help inform both the medical community and the public.  "If approved by the FDA, lorcaserin will provide an additional tool to fill the gap between lifestyle intervention alone at one end and bariatric surgical intervention at the other end," said Dr. Robert Kushner, past president of The Obesity Society.  Dr. Kushner provided public comment to the advisory committee on behalf of The Obesity Society.

About The Obesity Society

The Obesity Society (www.obesity.org) is the leading scientific organization in North America dedicated to the study of obesity. The Obesity Society is committed to encouraging research on the causes and treatment of obesity and keeping the medical community and public informed of new advances. The Obesity Society's vision is to be the leader in understanding, preventing and treating obesity and in improving the lives of those affected. The Obesity Society's membership comprises approximately 2500 basic and clinical researchers, who have published extensively, and care providers in obesity treatment and prevention.

The Article Referenced in this News Release

Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
Patrick M. O'Neil, Steven R. Smith, Neil J. Weissman, Meredith C. Fidler, Matilde Sanchez, Jinkun Zhang, Brian Raether, Christen M. Anderson and William R. Shanahan
Obesity (2012); 20 7, 1426–1436. doi:10.1038/oby.2012.66
http://www.nature.com/oby/journal/v20/n7/full/oby201266a.html


'/>"/>
SOURCE The Obesity Society
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MedVantx MedStart™ Solves Problem Highlighted in Study Published in Journal of the American Board of Family Medicine - Expired Medications in Physician Office Sample Closets
2. Call for Entries: International Bureau for Epilepsy and UCB launch the 2012 Excellence in Epilepsy Journalism Award to recognize exceptional reporting on epilepsy
3. Elsevier and the Society for Vascular Surgery Announce Forthcoming Launch of Journal of Vascular Surgery: Venous and Lymphatic Disorders
4. NAMS Journal Menopause Reflects on the WHI 10 Years Later
5. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
6. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
7. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
8. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
9. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
10. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
11. Study Confirms Daniels Sharpsmart Helps Hospitals Reduce Carbon Footprint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve ... engagement.” The patient is doing more than filling out a survey; in many cases ... an increasing emphasis in health care and research on the importance of active engagement ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
Breaking Medicine News(10 mins):